A Single Site, Open-Label Study to Evaluate the Immunogenicity and Safety of Influenza Vaccine, CSL Limited in Healthy 'Adults' aged >18 to <60 years and in Healthy 'Older Adults' aged >60 years for the 2005 Northern Hemisphere Influenza Season
Latest Information Update: 22 Aug 2019
At a glance
- Drugs Influenza virus vaccine (Afluria) (Primary) ; Influenza virus vaccine (Afluria) (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors CSL
- 22 Aug 2019 New trial record